Powering the Microbiome Bio-Economy
Branchpoint Biosciences is building the standard for microbial quantification. We provide the essential precision layer for the $60B+ global probiotics, therapeutics, and diagnostics markets.
The Shift from Discovery to Manufacturing
The microbiome industry is maturing. As pharmaceutical and consumer companies move from R&D to commercial production, the demand for Quality Control (QC) and Validation is exploding. Current methods (like NGS) are too slow and expensive for routine industrial use. Branchpoint bridges this gap, providing the speed and specificity required to scale the next generation of Live Biotherapeutic Products (LBPs) and functional foods.
The New Gold Standard: qMA™
We have engineered a proprietary platform that replaces expensive, complex sequencing with rapid, scalable qPCR assays.
-
Scalable: High-throughput workflows for industrial manufacturing.
-
Precise: Absolute quantification for regulatory compliance.
-
Accessible: Compatible with standard equipment globally, ensuring rapid adoption.
Business Model: We generate revenue through a hybrid model of high-margin reagent sales (Product) and specialized assay design partnerships (Service), creating sticky, long-term relationships with key industry players.
Co-founders Dr. Benjamin Tully (CEO) and Dr. Christopher Corzett (CSO) bring over 15 years of specialized experience in microbial genomics. Combining deep scientific rigor with commercial vision, leadership is focused on executing a strategy that bridges the gap between academic rigor and industrial scale.
Partner in Our Growth We are actively expanding our commercial footprint, our paying customer base, and product library. To discuss the company roadmap and investment opportunities: info@branchpoint.bio
Disclaimer: This page contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected.